News Sentiment

ACRS sentiment intelligence

Aclaris Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.58 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+0.4% over one week, +29.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.4% Price digesting
Trend fit Trend active 29.2% over four weeks
Fair value 107.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 36
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 9
TradingKey 5
simplywall.st 5
Stock Titan 3
marketscreener.com 2
Moomoo 2
Quiver Quantitative 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 22
Analyst action 4
Regulatory and legal 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
MyChesCo Direct company coverage

Aclaris Expands Immunology Pipeline Ahead of Key Trial Data

Aclaris Therapeutics (Nasdaq: ACRS) is advancing its immunology pipeline with several mid- and late-stage clinical milestones expected this year. The company anticipates topline data for ATI-052 in asthma and atopic dermatitis and bosakitug in atopic dermatitis in the second half

Tone
Positive 70/100
Event
Market update
Published
16 May 2026 16:40
Source
MyChesCo
TradingView Direct company coverage

ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding

Aclaris Therapeutics, Inc. (ACRS) is advancing multiple late-stage immunology assets, including biologics and small molecules targeting dermatologic and respiratory diseases, towards key milestones in 2024. The company's pipeline features anti-TSLP and ITK inhibitors, and it expe

Tone
Positive 71/100
Event
Market update
Published
14 May 2026 17:09
Source
TradingView
TradingView Direct company coverage

ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026

Aclaris Therapeutics (ACRS) is progressing three novel compounds through clinical trials, targeting significant, underserved inflammatory and immunological (I&I) markets. These compounds, comprising both oral and biologic therapies, have demonstrated strong efficacy and safety. M

Tone
Positive 72/100
Event
Market update
Published
14 May 2026 16:09
Source
TradingView
Associated Press Direct company coverage

Aclaris: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
07 May 2026 11:07
Source
Associated Press